The present invention is directed to certain hydroisoindoline compounds
which are useful as neurokinin-1 (NK-1) receptor antagonists, and
inhibitors of tachykinin and in particular substance P. The invention is
also concerned with pharmaceutical formulations comprising these
compounds as active ingredients and the use of the compounds and their
formulations in the treatment of certain disorders, including emesis,
urinary incontinence, depression, and anxiety.
